Holdings
31
Concentrated
Top 10 weight
65%
Concentration
Strategy data
N/A
Not reported
Equity
95%
Asset allocation
Portfolio
6Sectors
6Large positions
63.1%Top: Pharmaceuticals & Biotechnology
0.0%Cash
Market-cap allocation
Large cap39%
Mid cap17%
Small cap36%
Asset allocation
Equity95%
Debt1%
Top holdings
10.9%
Divi's Laboratories Ltd.EQUITY
10.4%9.4%
6.2%
5.9%
Ajanta Pharma Ltd.EQUITY
5.2%Mankind Pharma Ltd.EQUITY
4.7%Clearing Corporation of India Ltd.DERIVATIVE
4.3%Dr. Lal Path Labs Ltd.EQUITY
4.1%3.8%
Rubicon Research Ltd.EQUITY
3.7%Abbott India Ltd.EQUITY
3.2%3.0%
2.8%
Sai Life Sciences LtdEQUITY
2.6%Cipla Ltd.EQUITY
2.4%Pfizer Ltd.EQUITY
2.3%2.2%
Anthem Biosciences Ltd.EQUITY
2.0%Global Health Ltd.EQUITY
1.8%Zydus Lifesciences Ltd.EQUITY
1.4%Fortis Healthcare Ltd.EQUITY
1.3%Lupin Ltd.EQUITY
1.2%0.96%
Orchid Pharma Ltd.EQUITY
0.91%0.90%
0.89%
Lenskart Solutions Ltd.EQUITY
0.68%Sagility Ltd.EQUITY
0.48%0.45%
Net Receivables / (Payables)DERIVATIVE
0.21%AI Smart summary
Portfolio read
- 95% equity.
- 31 disclosed positions across 6 classified equity sectors.
- Largest equity sector is Pharmaceuticals & Biotechnology at 63.1% of the portfolio.
Watchpoints
- Top 10 positions account for 65%, indicating high portfolio concentration.
- Small-cap exposure is 36%, which may increase volatility and liquidity risk.
- Sector concentration is elevated: Pharmaceuticals & Biotechnology represents 63%.
Auto-generated from fund metrics. Educational only - not investment advice.
Peer comparison
Comparable funds require category or compatible portfolio metadata. Explore comparable funds →
Sector exposure
Full industry / sector breakdown aggregated from the fund's holdings.
63.1%
26.6%
2.8%
0.9%
0.7%
0.5%